EN
Will Raised Revenue Guidance Change Haemonetics Stock Narrative
- Haemonetics reported second quarter fiscal 2027 sales of US$357.76 million and net income of US$46.31 million, then raised its full year reported revenue growth guidance to a range of 8% to 11% from 5% to 8%.
- Stronger organic revenue across plasma, blood management, and interventional technologies, together with expanded CSL collaboration and new regulatory clearances, points to growing reliance on recurring, procedure linked disposable and software revenue streams.
- We will now look at how Haemonetics’ raised fiscal 2027 revenue guidance might reshape the investment narrative around recurring growth.
Haemonetics Investment Narrative Recap
To own Haemonetics, you need to believe the plasma, blood management, and interventional portfolios can keep turning procedure volume into recurring disposables and software revenue. The raised fiscal 2027 revenue growth outlook to 8% to 11% signals management sees solid underlying demand. The key short term catalyst is continued adoption of systems like NexSys with Persona PLUS and TEG 6s, which tie directly to recurring usage.
The main near term risk still sits in margins and balance sheet flexibility. Tariff costs, higher self insured medical claims, and a meaningful debt load around US$1.2b can compress profitability if growth slows. If competitive pressure in vascular closure or interventional products intensifies, price concessions could hurt net margins and weaken the case for sustained earnings expansion.
The most relevant data point for this story is the latest quarterly report. Haemonetics posted Q2 fiscal 2027 revenue of US$357.76 million and net income of US$46.31 million, with both sales and earnings per share above the prior year period. Management then lifted full year reported revenue growth guidance to 8% to 11%, from 5% to 8%, on the back of this execution.
That combination of organic growth and higher guidance feeds directly into the existing catalysts around plasma systems, TEG 6s, and vascular closure adoption. It increases the focus on whether higher revenue can outpace cost headwinds and support margin stability while the company carries net leverage close to 2.7x EBITDA. For investors, the operational question is whether this pace of recurring, procedure linked revenue can be sustained as competitors respond.
Haemonetics' current earnings are US$96.3 million, and analysts expect this to reach US$248.7 million by 2029. This implies an earnings increase of about 2.6x. Consensus assumptions also point to forecast revenues of US$1.6 billion by 2029, based on a projected 6.1% yearly revenue growth rate.
Uncover why Haemonetics' fair value indicates a 4% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
One alternate view around Haemonetics focuses squarely on cost pressure rather than recurring growth. The most cautious analysts were modeling roughly 5.9% yearly revenue growth and about US$241.8 million of earnings by 2029, and saw required P/E multiples nearer 18.9x. That is a much more pessimistic setup. These forecasts all pre date the latest guidance raise, so you may want to compare how each storyline could shift as new information filters through.
Explore another Haemonetics fair value estimate, including one that suggests it could be worth just $124.50.
Reach Your Own Conclusion
Don't just follow the ticker; dig into the data and build a conviction that's truly your own.
- A great starting point for your Haemonetics research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- See our latest analysis for Haemonetics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Haemonetics' overall financial health at a glance.
Looking For More Ideas Beyond Haemonetics?
If the Haemonetics story has sharpened your focus on quality and resilience, it can be useful to benchmark it against a broader watchlist. The Simply Wall St Screener lets you filter for financial traits that matter to you so you can build a list that genuinely fits your risk tolerance and return goals.
- Target stability first and look through 29 resilient stocks with low risk scores that score well on resilience and balance sheet strength.
- If you are hunting for income opportunities, scan 8 dividend fortresses that combine higher yields with an emphasis on durability.
- For those willing to put in extra research time, cast a wider net across 19 high quality undiscovered gems that pair solid fundamentals with lower market attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com